Friday, November 13, 2026

NASA’s ESCAPADE Completes Powered Earth Flybys, Now En Route to Mars

NASA’s two ESCAPADE (Escape and Plasma Acceleration and Dynamics Explorers) spacecraft have each successfully completed a powered Earth flyby, using Earth’s gravity in combination with a sustained engine burn to slingshot themselves toward Mars. With these successful maneuvers complete, the twin spacecraft are on target to reach the Red Planet in September 2027.

“This is the first time NASA has used a powered Earth flyby to propel a spacecraft toward Mars, and we’ve now executed this maneuver twice, flawlessly, in just two days,” said Asal Naseri, acting associate flight director for the Heliophysics Division at NASA Headquarters in Washington.

In November 2026, each of NASA’s two ESCAPADE (Escape and Plasma Acceleration and Dynamics Explorers) spacecraft executed a powered flyby of Earth, combining Earth’s gravity with an engine burn, to slingshot itself toward Mars. The first spacecraft made its closest approach around 5 a.m. EST on Saturday, Nov. 7, and the second did so two days later, around 6 a.m. EST on Monday, Nov. 9. In this animation, each spacecraft’s approximately 9-minute trans-Mars injection burn appears as an orange arc along the spacecraft’s trajectory.

Advanced Space/Matt Bolliger

The two ESCAPADE spacecraft launched from Cape Canaveral Space Force Station in Florida on Nov. 13, 2025, when Earth and Mars were on opposite sides of the Sun. So instead of heading straight for the Red Planet, as most other Mars missions have done, both spacecraft entered a “loiter” or “Earth-proximity” orbit. They charted a first-of-its-kind, kidney-bean-shaped course around a place in space about a million miles from Earth called Lagrange point 2, which is a gravitational balancing point on the opposite side of Earth from the Sun. Then they headed back toward Earth to perform this gravitational slingshot maneuver around our planet once Earth and Mars were favorably aligned.

The ESCAPADE mission is pioneering a unique path to get to Mars. After launch in November 2025, the two ESCAPADE spacecraft looped around the Earth-Sun Lagrange point 2 (L2), in an “Earth-proximity” or “loiter” orbit that allowed the spacecraft to return to Earth in November 2026 and use our planet’s gravity to slingshot themselves to Mars.

Advanced Space/Matt Bolliger

“With this loiter orbit and Earth flyby, ESCAPADE is pioneering a new strategy for getting to Mars,” said Jeff Parker of Advanced Space, lead mission designer. “This method provides the flexibility to launch almost anytime and then use Earth’s gravity to get a boost to Mars, rather than waiting every two years to launch there directly when the planets are aligned.”

The first ESCAPADE spacecraft completed its close approach to Earth and its approximately 9-minute trans-Mars injection burn — the engine firing that commits the spacecraft to its path to Mars — at 5 a.m. EST on Nov. 7, when it was about 1,000 miles above the planet’s surface. The second spacecraft followed suit two days later, completing its close approach and engine burn at 6 a.m. EST on Nov. 9, when it was about 650 miles above the planet’s surface.

In the mission operations center at the University of California, Berkeley’s Space Sciences Laboratory (SSL), Robert Lillis, ESCAPADE’s principal investigator (bottom right), awaits a signal after the first spacecraft performed an engine burn that initiated a powered Earth gravity assist on Nov. 7, 2026. Also pictured in the foreground (from left to right) are SSL aerospace engineer Sasha Courtade, SSL mission operations manager Mark Lewis, and SSL mission operations engineer Brett Bonelli.

Alan Toth/UC Berkeley Space Sciences Laboratory

These powered flybys of Earth set both spacecraft on course for their 10-month cruise to Mars, culminating with their Mars orbit insertion burns planned for Sept. 7 and Sept. 9, 2027. Once in orbit around Mars, the two spacecraft will fly in formation to study how a million-mile-per-hour stream of material flowing from the Sun, known as the solar wind, interacts with the Martian environment and how that drives atmospheric loss at Mars.

“By better understanding how the solar wind affects the Martian environment, ESCAPADE’s findings could help us plan and prepare for future human exploration of the Red Planet,” said Michele Cash, ESCAPADE program scientist at NASA Headquarters.

The twin ESCAPADE spacecraft have already taken some science observations during their loiter orbit as they flew multiple times through Earth’s magnetotail, a part of our planet’s magnetic environment that gets stretched away from Earth, opposite the Sun, by the solar wind. During the 10-month trip to Mars, the spacecraft also will be able to study the dynamics of the solar wind between Earth and Mars.

Along the way, the spacecraft will perform a series of trajectory correction maneuvers to adjust their path and ensure they are on a precise course to rendezvous with Mars in September 2027.


With ESCAPADE’s trans-Mars injection burns complete, the two spacecraft (represented by the central, teal arc) are traveling away from Earth (represented by the inner, blue orbit) and headed toward Mars (represented by the outer, red orbit).

Advanced Space/Matt Bolliger

When they reach Mars, two days apart, each spacecraft will fire its engine for about 11 minutes to slow down and enter orbit around the planet. The spacecraft then will take several months to maneuver into their first science formation, where they will follow one another in the same orbit to study how the planet’s environment changes with time and location. Science operations are expected to begin in June 2028.

Six months later, the two spacecraft will shift into different orbits, with one traveling farther from Mars to observe the incoming solar wind and the other staying closer to the planet to study how Mars responds to the solar wind in real time. That science campaign is scheduled to last five months.

“This will be the first science mission to choreograph two orbiters around Mars, and the first time we will be able to make coordinated observations of the Martian environment from two different locations simultaneously,” said ESCAPADE’s principal investigator, Rob Lillis of the University of California, Berkeley.

Funded by NASA’s Heliophysics Division, ESCAPADE is part of the agency’s SIMPLEx (Small Innovative Missions for Planetary Exploration) program, which supports missions that explore the solar system in innovative ways with smaller budgets.

The University of California, Berkeley’s Space Sciences Laboratory leads the mission with key partners Rocket Lab; NASA’s Goddard Space Flight Center in Greenbelt, Maryland; Embry-Riddle Aeronautical University; Advanced Space; and Blue Origin.

“The ESCAPADE mission continues the scientific legacy of historical Mars missions with a dedicated team driving new innovations for its journey to and at the Red Planet,” said Skyler Kleinschmidt, ESCAPADE program executive at NASA Headquarters. 

Vanessa Thomas

Source: NASA’s ESCAPADE Completes Powered Earth Flybys, Now En Route to Mars - NASA Science

How Cancer Uses Antioxidants to Switch Off the Immune System

Free radicals have a bad reputation. For decades they have been described as damaging byproducts of metabolism, which is a large part of why antioxidant supplements became popular as a possible way to lower cancer risk. A study in Science adds a twist: some of the cells that fight cancer actually need these molecules to work, and tumors appear to take advantage of that.

T cells need a spark of reactive oxygen

T cells are immune cells that hunt down and destroy abnormal cells, including tumor cells. To switch into attack mode, they rely on chemical signals, and small amounts of reactive oxygen species (the group of molecules that includes free radicals) are among them.

Researchers at the University of Cambridge and Oregon Health & Science University examined the fluid surrounding cells inside tumors grown in mice. They found that the tumors create conditions that stop nearby T cells from activating. The key player is Peroxiredoxin 1 (PRDX1), a natural antioxidant protein. Cancer cells release large amounts of it, and it clears away the reactive oxygen species that T cells need. Without that signal, the T cells become less effective, so the tumor effectively builds a chemical shield.

What happened when the shield was removed

To test the idea, the team used CRISPR gene editing to create mouse cancer cells that could no longer make PRDX1. Immune cells became more active and tumor growth slowed. Some tumors that had resisted immunotherapy started to respond once the antioxidant defense was gone.

The researchers also looked for the same mechanism in people. They used three approaches: existing data on proteins released by human cancer cell lines, gene activity patterns across thousands of human tumors, and fluid collected from tumors surgically removed from patients. All three pointed the same way, suggesting that human cancers also release PRDX1 into their surroundings.

Why this matters for immunotherapy

Immunotherapies have transformed treatment for some patients, but many others get little or no benefit. This work offers one possible explanation: tumors that release PRDX1 may be suppressing the very T cells the treatment is meant to activate. As Professor Rahul Roychoudhuri put it, blocking this process made non-responding tumors start responding in the experiments, which makes the pathway worth pursuing as a drug target.

Dr. Robert Eil of Oregon Health & Science University suggests another direction: instead of antioxidants, pro-oxidants might help kick-start T cells against tumors.

A possible clue about antioxidant supplements

Large randomized trials of antioxidant supplements have not shown protection against cancer, and in some cases outcomes were worse. The new findings suggest one possible reason: removing too many reactive oxygen species could weaken the immune activation that helps fight tumors. The researchers stress that this does not prove supplements promote cancer. It shows how differently these molecules can behave in different biological settings.

What to keep in mind

·         The treatment effects were shown in mouse models. Evidence of the same mechanism in human cancers is supportive but not proof that blocking PRDX1 works in patients.

·         No PRDX1-targeting treatment has been shown to be safe or effective in people yet.

·         The authors advise that people with cancer should not change their diet, supplements or treatment based on these findings without speaking to a healthcare professional.

Sources

·         Press release (University of Cambridge): Cancer cells release antioxidants to prevent immune cells from destroying them

·         Paper: Wesolowski AJ, et al. “Tumor-derived antioxidants suppress immunity by depriving T cells of reactive oxygen species.” Science, 2026. DOI: 10.1126/science.adz8203 

Source: How Cancer Uses Antioxidants to Switch Off the Immune System